Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

China flag China · Delayed Price · Currency is CNY
31.02
-1.16 (-3.60%)
Jul 30, 2026, 12:15 PM CST
Market Cap3.86B -8.8%
Revenue (ttm)688.74M +27.0%
Net Income44.38M +5.9%
EPS0.37 +6.0%
Shares Out 120.00M
PE Ratio87.00
Forward PEn/a
Dividend0.10 (0.31%)
Ex-Dividend DateJun 25, 2026
Volume2,939,850
Open32.52
Previous Close32.18
Day's Range31.02 - 32.56
52-Week Range27.68 - 81.88
Beta0.06
Analystsn/a
Price Targetn/a
Earnings DateAug 25, 2026

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets; and raw m... [Read more]

Sector Healthcare
Founded 2003
Employees 553
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300584
Full Company Profile

Financial Performance

In 2025, SHE:300584's revenue was 671.05 million, an increase of 33.05% compared to the previous year's 504.36 million. Earnings were 42.06 million, an increase of 4.58%.

Financial Statements